HAEMATURIA and Augmentin


HAEMATURIA Symptoms and Causes

A urinalysis is a test of your urine. It is often done to check for a urinary tract infections, kidney problems, or diabetes. You may also have one during a checkup, if you are admitted to the hospital, before you have surgery, or if you are pregnant. It can also monitor some medical conditions and treatments.

A urinalysis involves checking the urine for

  • Its color
  • Its appearance (whether it is clear or cloudy)
  • Any odor
  • The pH level (acidity)
  • Whether there are substances that are not normally in urine, such as blood, too much protein, glucose, ketones, and bilirubin
  • Whether there are cells, crystals, and casts (tube-shaped proteins)
  • Whether it contains bacteria or other germs

Check out the latest treatments for HAEMATURIA

HAEMATURIA treatment research studies

Augmentin clinical trials, surveys and public health registries

Find Drug Side Effect reports

Augmentin Side Effects

Diarrhoea (341)
Pruritus (324)
Rash (236)
Pyrexia (227)
Jaundice (205)
Erythema (198)
Alanine Aminotransferase Increased (194)
Dyspnoea (186)
Urticaria (180)
Anaphylactic Shock (179)
Vomiting (173)
Aspartate Aminotransferase Increased (168)
Blood Alkaline Phosphatase Increased (164)
Nausea (152)
Abdominal Pain (145)
Hypotension (136)
Cholestasis (136)
Hepatitis Cholestatic (134)
Gamma-glutamyltransferase Increased (130)
Malaise (119)
Hypersensitivity (113)
Blood Bilirubin Increased (108)
Rash Maculo-papular (104)
Face Oedema (103)
Asthenia (98)
Hepatitis (96)
Toxic Skin Eruption (92)
Abdominal Pain Upper (89)
Anaphylactic Reaction (86)
Renal Failure Acute (79)
Chromaturia (78)
Oedema Peripheral (74)
Eosinophilia (74)
Purpura (73)
Angioedema (73)
Dizziness (71)
Anaemia (69)
Bronchospasm (69)
International Normalised Ratio Increased (69)
Thrombocytopenia (67)
Tachycardia (66)
Rash Erythematous (65)
Inflammation (63)
Oedema (63)
Fatigue (61)
Pain (54)
Dehydration (54)
Anorexia (53)
Death (53)
Blood Pressure Decreased (53)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

3rd day on augmentin and i'm getting chest pain didn't think it could be related and really bad nausea when I took it this morning. They don't list that as a side effect.

And it has blister now ,,,im afraid i dont know what to do,,,

Augmentin 625 ; ive been on it for 2 days,feeling sick and central chest pain [ like bad heartburn]

Augmentin 625: 2x a day I've been on it for 2 days. Experienced unexplained joint pains and swelling of my hands, feet & face. Can see flashes on my left eye on the 2nd day. Have also noticed that I always want to eat.

Buna imi poate spune si mie cineva ce contine augumentinu ca eu sunt alergica la amoxicilina

Can augmentine 625 mg twice daily for five days cause as a side effect Hyperthermia

Doctor had me take amoxicillin 500mg because of sinus infection. I toke 4x500mg for 10days. It cleared up the infection but I have had acute gout attacks for over a month. my feet/hands/wrists/knees have developed terrible pain to the point that I co

Due to elevated liver enzyme levels and an elevated ANA, my previous doctor gave me a diagnosis of autoimmune hepatitis. After reviewing my charts, my current doctor believes that it was an autoimmune response to 3 back-to-back courses of amoxicillin

Has anyone developed boday aches anda fever following only a second dose? I was perfectly fine,no fever just abronchial inflamation. feel horrible!

I am on it for second day too. Only side effects I have had was diarrhea, slight headache, and for some reason I have a herpes blister on my hand, which is where the virus lies dormant (until now). I am hoping the blister will go away right after I g

HAEMATURIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Conditions: Hematuria;   Bladder Cancer
Intervention: Drug: Valproic Acid
Outcome Measures: Thrombospondin-1 gene expression;   Angiogenesis, proliferation, and histone deacetylase activity markers
2 Unknown  Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
Conditions: Hematuria;   Dysuria;   Bladder Cancer
Outcome Measure:
3 Recruiting Alport Syndrome Treatments and Outcomes Registry
Condition: Alport Syndrome
Outcome Measure: Data Collection: natural history study
4 Recruiting Prospective Evaluation of Blunt Renal Injury in Children
Condition: Renal Injury
Intervention: Other: Attenuated bedrest
Outcome Measures: Hypertension;   Time to clear hematuria;   length of stay;   degree of injury;   complications
5 Recruiting Screening for Bladder Cancer
Condition: Bladder Cancer
Intervention: Other: Specimen and questionnaires only
Outcome Measure: Since the marker tests will only be administered to individuals with a positive Hemastix test, these are eight possible outcomes (one case with all negative marker tests and seven cases with as least one positive marker tests).
6 Recruiting Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Condition: Alport Syndrome
Outcome Measure: Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
7 Unknown  Diet Intervention in Food Sensitive Patients With IgA Nephropathy
Condition: IGA Nephropathy
Interventions: Dietary Supplement: Tailored diet;   Dietary Supplement: Low antigen content diet
Outcome Measures: Proteinuria;   Renal function;   IgA/IgG immune complexes, incl. glycosylation;   IgA/IgG to dietary antigens;   Hematuria
8 Recruiting Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
Condition: Urinary Tract Infections
Interventions: Drug: Fosfomycin 3 g;   Drug: Ciprofloxacin 500 mg
Outcome Measures: Bacteriuria;   Urinary Tract Infection;   Sepsis;   Pathogens present in urine and antimicrobial resistance;   Bacteremia;   Hematuria;   Hemospermia;   Rectal bleeding;   Urinary retention;   Difficulty for miction;   Genitourinary infections associated to fever (>38ºC);   Number of participants with adverse events
9 Unknown  Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection
Conditions: Pain;   Intensive Care, Neonatal
Interventions: Procedure: Percutaneous Suprapubic Aspiration;   Procedure: Urethral Catheterization
Outcome Measures: infant pain response, as measured by facial grimacing and changes in heart rate and oxygen saturation during the procedure;   success rate of obtaining a sample suitable for analysis;   adverse events, such as post-procedure Haematuria, haemorrhage, haematoma, peritonitis, bowel perforation, abdominal wall abscess, and induction of infection, bladder perforation, urethral knots;   success rate of procedure according to infant factors; gestational age and sex
10 Not yet recruiting Probiotics in IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Dietary Supplement: ProTectis;   Dietary Supplement: Gastrus
Outcome Measures: Change in albuminuria;   Change in renal function;   Change in IgA/IgG immune complexes;   Change in hematuria;   Change in immunological markers in blood;   Change in IBS (irritable bowel syndrome) symptoms
11 Unknown  Nitrofurantoin and Urinary Tract Infections (UTIs)
Condition: Urinary Tract Infections
Interventions: Drug: Nitrofurantoin;   Drug: Placebo
Outcome Measures: primary outcome: the frequency of symptomatic UTI's confirmed with a positive urine culture within 6 to 8 weeks after CISC teaching and implementation;   time (days after surgery) to development of symptomatic, culture documented UTI;   frequency of urine cultures positive for organism strains that are resistant to nitrofurantoin and other commonly used antibiotics.;   adherence to CISC;   patient perceptions regarding CISC;   frequency of adverse events related to CISC such as urethral pain, irritative voiding symptoms, hematuria;   frequency of adverse events related to daily nitrofurantoin exposure such as nausea, diarrhea, C. difficile colitis
12 Recruiting Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura
Condition: Purpura, Schoenlein-Henoch
Outcome Measure: Renal prognosis
13 Recruiting Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
Conditions: Overactive Bladder;   Bladder Cancer;   Synergo
Intervention: Other: Questionnaires, anticholinergic treatment, urodynamic study
Outcome Measures: OAB symptoms severity and urodynamic variables in failed medical treatment patients;   Synergo treatment variables and OAB severity;   OAB severity of symptoms and urodynamic variables in failed medical treatment patients;   OAB treatment satisfaction and urodynamic variables in failed medical treatment patients
14 Unknown  Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients
Conditions: HBV Coinfection;   HIV Infections
Interventions: Drug: raltegravir and tenofovir and lamivudine;   Drug: efavirenz+tenofovir+lamivudine
Outcome Measures: Frequency and severity of adverse events;   Change of plasma HIV-1 RNA levels;   Change of Peripheral blood CD4 cell counts;   Change of plasma HBV-DNA levels;   Change of serum total bilirubin levels(TBI);   Proportion of subjects with HBeAg seroconversion (HBeAg loss and presence of anti HBe);   Emergence of drug resistance mutations, if appropriate;   Paired liver biopsy comparison according to inflammatory activity and fibrosis score;   Change of serum alanine aminotransferase levels (ALT);   Change of serum aspartate aminotransferase levels (AST);   Change of blood urine nitrogen levels (BUN);   Change of serum creatinine levels (SCr);   Change of blood haemoglobin levels (HB);   Change of white blood cell counts (WBC);   Change of blood platelet counts (PLT);   Change of urine protein levels
15 Recruiting Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures
Conditions: Other Acute Pain;   Pain Experienced During Cystoscopy
Intervention: Drug: Fentanyl pectin
Outcome Measures: Change from baseline in pain numeric rating scale;   Oxyhemoglobin saturation
16 Not yet recruiting Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
Condition: Nephrolithiasis
Interventions: Drug: Mirabegron;   Drug: Tamsulosin;   Drug: Percocet
Outcome Measures: Ureteral stent related pain and lower urinary tract symptoms (LUTS) as measured by the Ureteral Stent Symptom Questionnaire.;   Quality of life impact of mirabegron for stent symptoms as measured with the Ureteral Stent Symptoms Questionnaire.
17 Recruiting Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564);   Biological: Lenalidomide;   Biological: Dexamethasone;   Biological: Bortezomib
Outcome Measures: Determination of maximum tolerated dose;   Safety and tolerability will be analyzed for all patients. Safety endpoints will be based on adverse event reports, and include frequent adverse event (AE)s, serious adverse event (SAE)s and lab abnormalities;   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be maximum observed concentration (Cmax);   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be trough observed concentration (Cmin);   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be time of maximum observed concentration (Tmax);   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be area under the concentration-time curve in one dosing interval (AUC (TAU));   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be half-life (T-Half);   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF));   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be total body clearance (CLT);   Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be volume of distribution at steady-state (Vss);   Individual tumor responses as defined by the International Myeloma Working Group Uniform Response Criteria (IMWG) for Multiple Myeloma (MM) will be used to monitor efficacy. For this assessment blood urine, and/or bone marrow assessment will be used;   Anti-tumor response will be assessed by IMWG criteria (blood and urine; Bone marrow will not be collected unless to confirm complete response (CR));   Anti-tumor response will be assessed by IMWG criteria (blood and urine; Bone marrow assessment will be collected during screening period, at end of cycle 1, end of cycle 4 and to confirm CR );   Samples will be collected to characterize immunogenicity;   Baseline level of cytokines/chemokines/growth factors will be determined, but not limited to SDF1 in peripheral blood and bone marrow
18 Not yet recruiting A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
Condition: Purpura, Thrombocytopaenic, Idiopathic
Interventions: Drug: Belimumab;   Drug: Normal saline placebo
Outcome Measures: Platelet count;   Anti-platelet autoantibodies;   Platelet count (time);   Platelet count (incidence);   Platelet count (incidence of complete response);   Platelet count (incidence of doubling);   Vital signs;   Clinical chemistry and haematology;   Immunogenicity;   Serum concentrations of belimumab;   Serum and/or platelet bound anti-platelet antibodies;   B cell and T cell sub-populations and B lymphocyte stimulator (BLyS) receptor;   Antigen-specific B cells and T cells;   Serum cytokine/chemokine profile;   Transcriptome profile;   Autoantibody profile